ArticleJournal of cellular and molecular medicine2011
Metabolic profiling reveals key metabolic features of renal cell carcinoma.
Article in Journal of cellular and molecular medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
66 citing papers in PubMed, 1 synthesis or guideline pooled it, 114 citations in OpenAlex.
- Metabolism of kidney cancer: from the lab to clinical practice.European urology · 2013Pooled it
- Nuclear Magnetic Resonance metabolomics reveals an excretory metabolic signature of renal cell carcinoma.Scientific reports · 2016Trial
- Distinct protein and metabolic profiles in patients with advanced clear-cell renal cell carcinoma treated with sunitinib: a study of the Spanish oncology genitourinary group.Frontiers in oncology · 2026Article
- Tumour sampling conditions perturb the metabolic landscape of clear cell renal cell carcinoma.Nature communications · 2025Article
- Novel role of L-2-HG in regulating HIF1A signaling pathway and iron death resistance in renal cancer brain metastasis.Cell death & disease · 2025Article
- Efficient extraction via titanium organic frameworks facilitates in-depth profiling of urinary exosome metabolite fingerprints.Analytical and bioanalytical chemistry · 2025Article
- Metabolic signature of renal cell carcinoma tumours and its correlation with the urinary metabolome.Metabolomics : Official journal of the Metabolomic Society · 2025Article
- Metabolomics for the Identification of Biomarkers in Kidney Diseases.Nanotheranostics · 2025Review
- A Multiomics, Molecular Atlas of Breast Cancer Survivors.Metabolites · 2024Article
- The mechanism of liver X receptor regulates the balance of glycoFAsynthesis and cholesterol synthesis in clear cell renal cell carcinoma.Clinical and translational medicine · 2023Article
- Disentangling the Complexity of Nutrition, Frailty and Gut Microbial Pathways during Aging: A Focus on Hippuric Acid.Nutrients · 2023Review
- System biology approaches identified novel biomarkers and their signaling pathways involved in renal cell carcinoma with different human diseases.Bioscience reports · 2022Article
- Article
- Molecular signature of renal cell carcinoma by means of a multiplatform metabolomics analysis.Biochemistry and biophysics reports · 2022Article
- Two-dimensional correlated spectroscopy distinguishes clear cell renal cell carcinoma from other kidney neoplasms and non-cancer kidney.Translational andrology and urology · 2022Article
- Prevention of Cognitive Frailty in Patients of Older Age Groups after Open-Heart Surgery under Cardiopulmonary Bypass.Archives of Razi Institute · 2022Article
- Proline Dehydrogenase/Proline Oxidase (PRODH/POX) Is Involved in the Mechanism of Metformin-Induced Apoptosis in C32 Melanoma Cell Line.International journal of molecular sciences · 2022Article
- Metformin Induces PRODH/POX-Dependent Apoptosis in Breast Cancer Cells.Frontiers in molecular biosciences · 2022Article
- Article
- Proline oxidase silencing inhibits p53-dependent apoptosis in MCF-7 breast cancer cells.Amino acids · 2021Article
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent evidence suggests that metabolic changes play a pivotal role in the biology of cancer and in particular renal cell carcinoma (RCC). Here, a global metabolite profiling approach was applied to characterize the metabolite pool of RCC and normal renal tissue. Advanced decision tree models were applied to characterize the metabolic signature of RCC and to explore features of metastasized tumours. The findings were validated in a second independent dataset. Vitamin E derivates and metabolites of glucose, fatty acid, and inositol phosphate metabolism determined the metabolic profile of RCC. α-tocopherol, hippuric acid, myoinositol, fructose-1-phosphate and glucose-1-phosphate contributed most to the tumour/normal discrimination and all showed pronounced concentration changes in RCC. The identified metabolic profile was characterized by a low recognition error of only 5% for tumour versus normal samples. Data on metastasized tumours suggested a key role for metabolic pathways involving arachidonic acid, free fatty acids, proline, uracil and the tricarboxylic acid cycle. These results illustrate the potential of mass spectroscopy based metabolomics in conjunction with sophisticated data analysis methods to uncover the metabolic phenotype of cancer. Differentially regulated metabolites, such as vitamin E compounds, hippuric acid and myoinositol, provide leads for the characterization of novel pathways in RCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.